US20260008866
2026-01-08
Chemistry; metallurgy
C07K16/2896
The patent application discusses antibodies targeting PD-L2, a molecule involved in immune regulation, and their potential use in cancer treatment. PD-L2 is primarily expressed on antigen-presenting cells and can be upregulated by certain cytokines. Tumors exploit this pathway to evade immune detection by expressing PD-L2, which interacts with PD-1 on T cells, leading to immune suppression. The antibodies described in the application aim to block this interaction, thereby enhancing the immune response against tumors.
The antibodies or antibody fragments are characterized by specific heavy and light chain sequences that selectively bind to PD-L2. These sequences are detailed in various tables within the application. The antibodies may be single chain, domain antibodies, chimeric, or Fab fragments. They can be human, murine, or humanized versions, and may include labels such as peptide tags or fluorescent molecules for tracking purposes. Additionally, these antibodies can be linked to antitumor drugs using photolabile or enzymatically-cleaved linkers.
The application outlines a method for treating cancers that express PD-L2 by administering these antibodies to patients. The target cancer cells include a range of solid tumors and hematological malignancies. The treatment may be combined with other therapies like chemotherapy, radiotherapy, or immunotherapy to enhance efficacy. The antibodies may also be used against metastatic, drug-resistant, or recurrent cancer cells.
Various delivery methods for the antibodies are described, including direct administration or genetic delivery via RNA or DNA vectors. The antibodies may be delivered in forms such as recombinant scFv, Fab, or Fv fragments. These delivery methods aim to ensure that the antibodies effectively reach and bind to the PD-L2 molecules on cancer cells, thereby blocking the PD-1/PD-L2 interaction and promoting an immune response.
The application also mentions the development of hybridomas or engineered cells that produce the described antibodies. These cells are characterized by the same specific heavy and light chain sequences. Such engineered cells could be used for large-scale production of the antibodies, facilitating their use in therapeutic applications. This approach underscores the potential for these antibodies to be developed into viable treatments for various cancers.